First-generation Paclitaxel- Vs. Second-generation Zotarolimus-eluting Stents in Small Coronary Arteries: the BASKET-SMALL Pilot Study

Overview

Journal Postepy Kardiol Interwencyjnej

Publisher Termedia

Specialty Cardiology & Vascular Diseases

Date 2016 Dec 17

PMID 27980544

Citations 4

Authors

Raban Jeger

Matthias Pfisterer

Otmar Pfister

Peter Rickenbacher

Michael Handke

Nicole Gilgen

Michael Coslovsky

Christoph Kaiser

Affiliations

Soon will be listed here.

Abstract

Introduction: Event rates after percutaneous coronary interventions (PCI) are higher in small than large coronary vessels but may vary between different drug-eluting stent (DES) types.

Aim: To assess the efficacy of two different DES in small vessel disease.

Material And Methods: Patients with small vessel PCI were randomised 1 : 1 to a first-generation paclitaxel- vs. a second-generation zotarolimus-eluting stent. The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction, and target vessel revascularisation after 2 years.

Results: Overall, 191 patients were enrolled: 100 with a paclitaxel- and 91 with a zotarolimus-eluting stent. Baseline characteristics were similar in both groups. After 2 years, rates of the primary endpoint were numerically higher for zotarolimus- than paclitaxel-eluting stents (9.9% vs. 5.0%, hazard ratio 2.09, 95% confidence interval (CI) 0.7-6.2, = 0.19), which was mainly driven by higher rates of target vessel revascularisation (6.6% vs. 2.0%, hazard ratio 3.39, 95% CI: 0.68-16.78, = 0.14). Based on this, a total of 1,019 patients would be necessary to demonstrate at least non-inferiority between the DES used.

Conclusions: In this pilot study, paclitaxel-eluting stents had a favourable efficacy profile in small vessel disease, although the numbers were too small to draw final conclusions. Based on the prohibitively high sample size for a randomized controlled trial between DES, other treatment options should be considered.

Citing Articles

Small Vessel Coronary Artery Disease: Rationale for Standardized Definition and Critical Appraisal of the Literature.

Sanz-Sanchez J, Chiarito M, Gill G, van der Heijden L, Pina Y, Cortese B J Soc Cardiovasc Angiogr Interv. 2024; 1(5):100403.

PMID: 39131458 PMC: 11307687. DOI: 10.1016/j.jscai.2022.100403.

Serum Copper/Zinc Ratio in Overweight and Obese Children: a Cross-Sectional Study.

Du M, Qiu M, Qian Y, Wang T, Chen X Biol Trace Elem Res. 2023; 202(4):1539-1549.

PMID: 37505435 DOI: 10.1007/s12011-023-03790-1.

Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2.

Gilgen N, Farah A, Scheller B, Ohlow M, Mangner N, Weilenmann D Clin Cardiol. 2018; 41(5):569-575.

PMID: 29527709 PMC: 6001703. DOI: 10.1002/clc.22942.

[Comparison of limus-eluting stent with paclitaxel-eluting stent for patients with coronary small vessel disease:a systematic review and meta-analysis].

Zhang X, Wang Q, Wang X, Xu X, Zhu J Zhejiang Da Xue Xue Bao Yi Xue Ban. 2017; 46(3):305-314.

PMID: 29039175 PMC: 10396921. DOI: 10.3785/j.issn.1008-9292.2017.06.14.

References

Daemen J, Garcia-Garcia H, Kukreja N, Imani F, De Jaegere P, Sianos G . The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J. 2006; 28(1):26-32. DOI: 10.1093/eurheartj/ehl412. View

Tanimoto S, Serruys P, Thuesen L, Dudek D, De Bruyne B, Chevalier B . Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2007; 70(4):515-23. DOI: 10.1002/ccd.21136. View

Siontis G, Piccolo R, Praz F, Valgimigli M, Raber L, Mavridis D . Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis. JACC Cardiovasc Interv. 2016; 9(13):1324-34. DOI: 10.1016/j.jcin.2016.03.025. View

Silber S, Albertsson P, Aviles F, Camici P, Colombo A, Hamm C . Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005; 26(8):804-47. DOI: 10.1093/eurheartj/ehi138. View

Cannon L, Kereiakes D, Mann T, Popma J, Mooney M, Mishkel G . A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial. EuroIntervention. 2011; 6(8):920-7, 1-2. DOI: 10.4244/EIJV6I8A161. View

Heinze G, Schemper M . A solution to the problem of monotone likelihood in Cox regression. Biometrics. 2001; 57(1):114-9. DOI: 10.1111/j.0006-341x.2001.00114.x. View

Byrne R, Joner M . Drug-Coated Balloon Angioplasty for De Novo Stenosis: The Balloon is Back…Reloaded!. JACC Cardiovasc Interv. 2015; 8(15):2010-2012. DOI: 10.1016/j.jcin.2015.10.013. View

Mehran R, Rao S, Bhatt D, Gibson C, Caixeta A, Eikelboom J . Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123(23):2736-47. DOI: 10.1161/CIRCULATIONAHA.110.009449. View

Stone G, Ellis S, Cannon L, Mann J, Greenberg J, Spriggs D . Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005; 294(10):1215-23. DOI: 10.1001/jama.294.10.1215. View

10.

Wessely R, Schomig A, Kastrati A . Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol. 2006; 47(4):708-14. DOI: 10.1016/j.jacc.2005.09.047. View

11.

Morice M, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G . Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA. 2006; 295(8):895-904. DOI: 10.1001/jama.295.8.895. View

12.

Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A . Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004; 292(22):2727-34. DOI: 10.1001/jama.292.22.2727. View

13.

Byrne R, Joner M, Alfonso F, Kastrati A . Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2013; 11(1):13-23. DOI: 10.1038/nrcardio.2013.165. View

14.

Kaul U, Bangalore S, Seth A, Arambam P, Abhaichand R, Abhaychand R . Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes. N Engl J Med. 2015; 373(18):1709-19. DOI: 10.1056/NEJMoa1510188. View

15.

Stankovic G, Cosgrave J, Chieffo A, Iakovou I, Sangiorgi G, Montorfano M . Impact of sirolimus-eluting and Paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. Am J Cardiol. 2006; 98(3):362-6. DOI: 10.1016/j.amjcard.2006.01.104. View

16.

Ong A, Aoki J, van Mieghem C, Rodriguez Granillo G, Valgimigli M, Tsuchida K . Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol. 2005; 96(3):358-62. DOI: 10.1016/j.amjcard.2005.03.075. View

17.

Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H . Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med. 2010; 363(24):2310-9. DOI: 10.1056/NEJMoa1009406. View

18.

Tanimoto S, Daemen J, Tsuchida K, Garcia-Garcia H, de Jaegere P, van Domburg R . Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: insight into the RESEARCH and T-SEARCH registries. Catheter Cardiovasc Interv. 2006; 69(1):94-103. DOI: 10.1002/ccd.20907. View

19.

Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits P . Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. J Am Coll Cardiol. 2015; 65(23):2496-507. DOI: 10.1016/j.jacc.2015.04.017. View

20.

Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F . A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol. 2012; 60(24):2473-80. DOI: 10.1016/j.jacc.2012.09.020. View